The medical technology startup Vantis, situated in San Jose, California, has secured $5 million in Safe (Simple Agreement for Future Equity) funding.
Use of funds
With this investment, the business hopes to enhance patient outcomes and expand the profession of interventional cardiology, having raised a total of $24 million so far via grants from the NIH and private donors.
About Vantis
Vantis Vascular is a medical technology firm headed by CEO Jason Turner and Chief Medical Officer Tim Fischell, MD, with the goal of enhancing vascular treatments via the use of performance-driven solutions. The CrossFASTTM Integrated Microcatheter Guide Extension System and the CrossSHOCKTM Intravascular Lithotripsy (IVL) System are two of its flagship products that are currently in development.
The CrossSHOCK IVL System optimizes the IVL experience by using a low profile, micro electrode design, while the CrossFAST Integrated Microcatheter Guide Extension System, with its 2-in-1 DuoProTM Interlocking Technology, gives interventionalists enhanced control and maneuverability to navigate the most calcific and tortuous anatomies. Both systems aim to treat calcified arteries in a safer, faster, and more effective manner. Large and expanding cardiovascular markets, including the multibillion-dollar IVL potential, are served by both devices.
The products are not yet commercially available for sale in any region; they are still in the development stage.
“This financing underscores the confidence of our investors in our vision, experienced management team, and the potential of our technologies to drive innovation and make a lasting impact in vascular interventions. This round will assist the near-term commercial launch of our CrossFAST technology and help us expedite our development activities.”
Jason Turner
